| human | Q5 |
| P496 | ORCID iD | 0000-0002-0868-9928 |
| P1153 | Scopus author ID | 7004388779 |
| P108 | employer | University of Sydney | Q487556 |
| P734 | family name | Morley | Q16279729 |
| Morley | Q16279729 | ||
| Morley | Q16279729 | ||
| P735 | given name | Kirsten | Q256744 |
| Kirsten | Q256744 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q51073688 | (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. |
| Q110657563 | A Content Analysis of Reddit Users' Perspectives on Reasons for Not Following Through with a Suicide Attempt |
| Q47097514 | A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). |
| Q40489471 | Alcohol use disorders in Australia. |
| Q36718979 | Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety |
| Q38796222 | Biased and less sensitive: A gamified approach to delay discounting in heroin addiction |
| Q90611687 | Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study |
| Q50119266 | Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users |
| Q46594093 | Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? |
| Q89710797 | Drinking risk varies within and between Australian Aboriginal and Torres Strait Islander samples: a meta-analysis to identify sources of heterogeneity |
| Q89204766 | Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis |
| Q104077006 | Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review |
| Q91270879 | Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review |
| Q46095530 | Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence. |
| Q104578101 | Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in Young Adults: Lack of Association With Alcohol Consumption |
| Q44683191 | Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. |
| Q89599710 | Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review |
| Q40561021 | Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. |
| Q43832354 | Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). |
| Q44050776 | Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion |
| Q34245795 | Integrated care for comorbid alcohol dependence and anxiety and/or depressive disorder: study protocol for an assessor-blind, randomized controlled trial |
| Q55001048 | Intolerance of uncertainty and conditioned place preference in opioid addiction. |
| Q38398416 | Is Specialized Integrated Treatment for Comorbid Anxiety, Depression and Alcohol Dependence Better than Treatment as Usual in a Public Hospital Setting? |
| Q37081083 | Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study |
| Q44340181 | Learning and generalization from reward and punishment in opioid addiction |
| Q89398509 | Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial |
| Q90309418 | N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research |
| Q39618340 | National trends in alcohol pharmacotherapy: Findings from an Australian claims database |
| Q37457289 | Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial |
| Q30235058 | Pharmacotherapeutic agents in the treatment of methamphetamine dependence. |
| Q45121451 | Preexposure to MDMA ("Ecstasy") delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. |
| Q24197576 | Psychosocial interventions for people with both severe mental illness and substance misuse |
| Q37451534 | Psychosocial interventions for people with both severe mental illness and substance misuse. |
| Q52316875 | Psychostimulant-related health service demand in an inner-city hospital, 2012-2015. |
| Q38650566 | Reward and punishment-based compound cue learning and generalization in opiate dependency |
| Q42744198 | Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. |
| Q38993198 | Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence |
| Q44243620 | The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. |
| Q43523661 | The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. |
| Q43935568 | The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: a multisite randomized controlled trial |
| Q47919985 | The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. |
| Q58773960 | Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study) |
| Q52315918 | Translating evidence-based practice for managing comorbid substance use and mental illness using a multi-modal training package. |
Search more.